Amantadine for the treatment of refractory absence seizures in children

Area of Science:

• Neurology
• Pediatric Epilepsy
• Pharmacology

Background:

• Refractory absence seizures pose significant treatment challenges in pediatric populations.
• Existing antiepileptic drugs (AEDs) may have limited efficacy or significant side effects.
• Amantadine has shown promise in smaller studies for certain seizure types.

Purpose of the Study:

• To evaluate the efficacy of amantadine as a treatment for refractory absence seizures in pediatric patients.
• To assess the percentage of seizure reduction at multiple time points after amantadine initiation.
• To identify potential patient characteristics or treatment outcomes associated with amantadine response.

Main Methods:

• Retrospective review of medical records for pediatric patients with absence seizures treated with amantadine.
• Data collection included patient demographics, concomitant AEDs, amantadine dosage, and seizure frequency.
• Outcomes were categorized based on seizure reduction percentages (>90%, ≥50%, <50%) at 3, 6, and 12 months.

Main Results:

• 13 pediatric patients with refractory absence seizures were included in the study.
• Over 50% of patients achieved at least a 50% reduction in seizure frequency at 3, 6, and 12 months.
• A majority of responders experienced greater than 90% seizure reduction.

Conclusions:

• Amantadine demonstrated significant efficacy in reducing seizure frequency in pediatric patients with refractory absence seizures.
• Amantadine may serve as a viable alternative treatment option for this challenging patient group.
• Further prospective studies are warranted to confirm these findings and optimize amantadine use.